Subject: Selective Internal Radiation Therapy (SIRT)*

Effective Date: April 28, 2009

Department(s): Utilization Management

Policy: Selective Internal Radiation Therapy (SIRT) with $^{90}$yttrium-containing resin spheres is reimbursable under Plans administered by QualCare, Inc.

Objective: To assure proper and consistent reimbursement and to delineate circumstances under which a specific therapeutic intervention is to be authorized.

Procedure:

A. Diagnoses for which SIRT is reimbursable are:
   
   1. Primary hepatocellular carcinoma (ICD-9 155.0)
   2. Metastatic hepatic lesions arising from colorectal cancer (ICD-9 197.7)

B. SIRT is not reimbursable for any other indication

C. CPT codes applicable to SIRT are:
   
   1. C2616 (for the $^{90}$yttrium-containing resin spheres)
   2. S2095 (for the deployment of the spheres)

References

Venook AP. Nonsurgical treatment strategies for colorectal cancer liver metastases. *UpToDate* v 16.3 2008 (Oct 1). Available at [www.uptodate.com/online/content/topic.do?topicKey=gicancer/5245&view=print]. Accessed 03/20/09


Welsh JS, Kennedy AS, Thomadsen B. Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. *Int J Radiat Oncol Biol Phys* 2006;66(2Suppl):S62-S73 (Jan)

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.*